Pacira Pharmaceuticals, Inc.

10450 Science Center Drive
San Diego, CA 92121
(858) 625 2424

5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560

TAKING CARE OF PATIENTS, TODAY AND TOMORROW

Online Investor Kit

Assemble your own Investor Kit by selecting and printing from the following documents.

Corporate Presentation

DateTitle
04/08/14
2014 Corporate Presentation

Recent SEC Filings

<< First | Previous | Next | Last >>
Filing DateFormDescriptionFiling GroupDownloads
04/09/148-KReport of unscheduled material events or corporate eventCurrent Reports Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
04/09/14424B5Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3Registration Statements Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
04/07/14424B5Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3Registration Statements Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
04/07/14S-3ASRS-3ASRRegistration Statements Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
04/07/148-KReport of unscheduled material events or corporate eventCurrent Reports Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
<< First | Previous | Next | Last >>
There are currently no items available.

Fact Sheets

DateTitle
03/18/14
Corporate Fact Sheet  PDF
01/20/12
EXPAREL® Fact Sheet PDF
05/03/13
DepoFoam® Backgrounder PDF
05/06/11
Postsurgical Pain Backgrounder PDF

Recent Press Releases

DateTitle 
04/17/14Pacira Pharmaceuticals Announces Timing for First Quarter 2014 Financial Results Webcast and Conference Call
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 17, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that financial results for the company’s first quarter ended March 31, 2014, will be released before the market opens on Thursday, May 1, 2014. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Thursday, May 1, 2014, at 9 a.m. ET. The call can be acces... 
Printer Friendly Version
04/15/14Pacira Pharmaceuticals Announces Grants of Inducement Stock Options Under NASDAQ Listing Rule 5635(c)(4)
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 15, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that on April 15, 2014, it approved the grant of stock options to 17 new employees to purchase an aggregate of 81,000 shares of common stock. The stock options were granted as inducements material to the new employees entering into employment with Pacira, as permitted under NASDAQ Listing Rule 5635(c)(4). Pacira granted to 17 new ... 
Printer Friendly Version
04/08/14Pacira Pharmaceuticals Announces Pricing of Public Offering of Common Stock
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 8, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the pricing of its previously announced public offering of 1,600,000 shares of its common stock at a public offering price of $64.00 per share. After deducting underwriting discounts and commissions and estimated offering expenses, Pacira will receive net proceeds of approximately $96.0 million in the offering. In addition, Pacira has granted the... 
Printer Friendly Version
04/07/14Pacira Pharmaceuticals Announces Proposed Public Offering of Common Stock
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 7, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that it is offering $100 million of its common stock in a proposed underwritten public offering. In addition, Pacira intends to grant the underwriters a 30-day option to purchase up to $15 million of additional shares of common stock. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may... 
Printer Friendly Version
04/07/14Pacira Pharmaceuticals Enters into Strategic Co-Production Partnership with Patheon to Create Additional EXPAREL Manufacturing Capacity
New Manufacturing Facility to Meet Future Demand Exceeding the Estimated $400 Million of Current Production Capacity PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 7, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced entering into a strategic co-production partnership with Patheon, the pharmaceutical services business owned by DPx Holdings B.V., to manufacture and package EXPAREL® (bupivacaine liposome injectable suspension) a... 
Printer Friendly Version
04/04/14EXPAREL Use in Femoral Nerve Block for Total Knee Arthroplasty Further Supported by Additional Data from Phase 3 Pivotal Study, sNDA Submission Planned for Second Quarter 2014
Data Presented at the 39th Annual Meeting of the American Society of Regional Anesthesia and Pain Medicine PARSIPPANY, N.J. & CHICAGO--(BUSINESS WIRE)--Apr. 4, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced additional Phase 3 data supporting the efficacy and safety of EXPAREL® (bupivacaine liposome injectable suspension) to achieve a femoral nerve block in patients undergoing total knee arthroplasty. The Company ... 
Printer Friendly Version
03/31/14Pacira Pharmaceuticals, Inc. Announces FDA Approval of Additional Manufacturing Suite for EXPAREL
PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 31, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the U.S. Food and Drug Administration (FDA) approved an additional bulk manufacturing suite, referred to as Suite C, for EXPAREL® (bupivacaine liposome injectable suspension). The suite is housed at the company’s Science Center Campus in San Diego, where EXPAREL is currently manufactured. “We believe the approval of an ... 
Printer Friendly Version
03/14/14Two New Studies Support Use of EXPAREL for Postsurgical Pain Management Following Total Joint Replacement
Data Presented at 2014 Annual Meeting of the American Academy of Orthopedic Surgeons Show EXPAREL Improved Pain Scores, Lowered Opioid Consumption, and Reduced Hospital Stays, Falls and Overall Costs PARSIPPANY, N.J. & NEW ORLEANS--(BUSINESS WIRE)--Mar. 14, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced new data evaluating the use of EXPAREL® (bupivacaine liposome injectable suspension) to manage postsurgical pain ... 
Printer Friendly Version
03/06/14Pacira Pharmaceuticals Inc. Appoints Industry Expert Yvonne Greenstreet to its Board of Directors
PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 6, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the appointment of Yvonne Greenstreet, MBChB, MBA, to its board of directors. “We are delighted to have Yvonne join as our newest board member,” said Dave Stack, president, chief executive officer and chairman of Pacira. “We believe that her vast experience working across a diverse range of critical functions at some of the most est... 
Printer Friendly Version
03/05/14Pacira Pharmaceuticals Announces EXPAREL® Data Presentations at 2014 Annual Meeting of the American Academy of Orthopedic Surgeons
Studies Assess Impact of EXPAREL on Postsurgical Pain and Health Economic Outcomes Following Total Knee and Hip Replacement Procedures PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 5, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that data evaluating the use of EXPAREL® (bupivacaine liposome injectable suspension) to manage postsurgical pain following knee and hip arthroplasty (replacement) procedures will be presented at... 
Printer Friendly Version
>> Access Older Press Releases